<DOC>
	<DOC>NCT02427516</DOC>
	<brief_summary>To estimate annualized total cost rates (i.e. direct medical costs from hospitalizations, consultations, medications, and tests) of adequately controlling a patient (i.e. INR between 2-3 and TTRâ‰¥ 60%) diagnosed with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE), and treated with vitamin K antagonists (VKA) in Spain.</brief_summary>
	<brief_title>Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain</brief_title>
	<detailed_description />
	<mesh_term>Vitamin K</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Patients aged 18 or older over the study period Patients with a diagnosis for NVAF or VTE anytime in their medical records Patients having at least one year of enrolment in the database prior to the index date Patients newly initiated with VKA during the study period (index date) Patients with a diagnosis for both NVAF and VTE anytime in their medical records</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>